Full text is available at the source.
Abstract
Obesity is a chronic disease with significant variability in responses to anti-obesity medications.
- GLP-1 receptor agonists and dual incretin agonists can lead to substantial average weight loss in clinical trials.
- Real-world effectiveness of these medications may be limited by factors such as gastrointestinal intolerance and cost barriers.
- Incomplete dose escalation and poor long-term persistence are common issues faced by patients using these medications.
- Weight regain is frequently observed after treatment discontinuation, highlighting the need for ongoing management in obesity treatment.
Simplified